BioCryst to Present at J.P. Morgan Healthcare Conference

  BioCryst to Present at J.P. Morgan Healthcare Conference

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- January 2, 2013

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Jon
Stonehouse, President and Chief Executive Officer of BioCryst is scheduled to
present and provide a corporate summary and update regarding the Company at
the 31^st annual J.P. Morgan Healthcare Conference in San Francisco on
Thursday, January 10, 2012 at 10:30 a.m. Pacific Time.

Links to a live audio webcast and replay of the presentation may be accessed
on the BioCryst website events page at
http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule
drugs that block key enzymes involved in infectious and inflammatory diseases,
with the goal of addressing unmet medical needs of patients and physicians.
BioCryst currently has two late-stage development programs: peramivir, a viral
neuraminidase inhibitor for the treatment of influenza, and ulodesine, a
purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In
addition, BioCryst has several early-stage programs: BCX4161 and a next
generation oral inhibitor of plasma kallikrein for hereditary angioedema,
BCX4430, a broad spectrum antiviral for hemorrhagic fevers, and BCX5191, a
nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C. For
more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

Contact:

BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
 
Press spacebar to pause and continue. Press esc to stop.